Amphotericin B Patent Expiration
Amphotericin B was first introduced by Apothecon Inc Div Bristol Myers Squibb
Amphotericin B Patents
Given below is the list of patents protecting Amphotericin B, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Abelcet | US6406713 | Methods of preparing low-toxicity drug-lipid complexes |
Jun 18, 2019
(Expired) | Leadiant Biosci Inc |
| Ambisome | US5965156 | Amphotericin B liposome preparation |
Oct 12, 2016
(Expired) | Astellas |
| Ambisome | US5874104 | Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics |
Feb 23, 2016
(Expired) | Astellas |
| Abelcet | US5616334 | Low toxicity drug-lipid systems |
Apr 01, 2014
(Expired) | Leadiant Biosci Inc |
Amphotericin B's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Amphotericin B:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
